{
    "id": 29679,
    "fullName": "MAP3K1 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "MAP3K1 inact mut indicates that this variant results in a loss of function of the Map3k1 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4214,
        "geneSymbol": "MAP3K1",
        "terms": [
            "MAP3K1",
            "MAPKKK1",
            "MEKK",
            "MEKK 1",
            "MEKK1",
            "SRXY6"
        ]
    },
    "variant": "inact mut",
    "createDate": "04/14/2019",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16744,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ER/PR positive, ERBB2 (HER2) negative breast cancer harboring ERBB2 (HER2) G776V, PIK3CA H1047R, and two MAP3K1 frameshift mutations demonstrated a positive clinical response for 13 months when treated with a combination of Herceptin (trastuzumab), Perjeta (pertuzumab) and Aromasin (exemestane) (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017).",
            "molecularProfile": {
                "id": 31777,
                "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 8162,
                "therapyName": "Exemestane + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16745,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an ER/PR positive, ERBB2 (HER2) negative breast cancer patient harboring ERBB2 (HER2) G776V, PIK3CA H1047R, and two MAP3K1 frameshift mutations who progressed while being treated with Herceptin (trastuzumab), Perjeta (pertuzumab), and Aromasin (exemestane) demonstrated a clinical response for nearly six months when switched to Herceptin (trastuzumab), Perjeta (pertuzumab), and Abraxane (nab-paclitaxel) (Chudnovsky,Y et al. JCO Prec Onc, Aug 2017).",
            "molecularProfile": {
                "id": 31777,
                "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R"
            },
            "therapy": {
                "id": 8163,
                "therapyName": "Nab-paclitaxel + Pertuzumab + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14794,
                    "pubMedId": null,
                    "title": "Response of a Metastatic Breast Carcinoma With a Previously Uncharacterized ERBB2 G776V Mutation to Human Epidermal Growth Factor Receptor 2\u2013Targeted Therapy",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.16.00037"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31776,
            "profileName": "MAP3K1 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31777,
            "profileName": "ERBB2 G776V MAP3K1 inact mut PIK3CA H1047R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}